Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02551692 · ClinicalTrials.gov registry record · NA
Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 125
- Enrollment target
NCT02551692 is a NA study that has completed, run by Duke University. The registered enrollment target is 125 participants.
The verdict
NCT02551692, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 125 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the effects of varenicline versus nicotine replacement versus placebo on personal smoking environment cue (PSE) reactivity. The results of this study will inform whether first-line pharmacotherapies for nicotine dependence (e.g. nicotine patch, varenicline) alter reactivity to environment cues. The investigators propose to identify 120 regular cigarette smokers who will complete 10 visits (1 screening visit, 1 training visit, 1 camera turn-in 2 cue exposure sessions and 4 post-quit medication check sessions). Smokers will be randomized to one of three medication conditions: placebo (PLAC; n=40), transdermal nicotine patch (NRT; n=40) or varenicline (VAR; n=40) in a double blind, double-dummy design. Reactivity variables (craving, latency to smoke, and smoke intake) will be entered into 3 (Medication: NRT, VAR, PLAC) x 2 (Environment: smoking, nonsmoking) repeated measures ANOVAs with random-effects. The investigators hypothesize that personal smoking, as compared to nonsmoking environments, will be associated with greater reactivity (i.e. increased craving and smoke intake; decreased latency to smoke). A Medication x Environment interaction will be characterized by decreased reactivity to smoking as compared to nonsmoking environments in the VAR and NRT groups as compared to the PLAC group.
Interventions
- DRUG Varenicline
- DRUG Placebo Nicotine Patch
- DRUG Nicotine Patch
- DRUG Placebo Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-01-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02551692
The ClinicalTrials.gov registry entry for NCT02551692 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Varenicline is the first listed.
NCT02551692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02551692 about?
NCT02551692 is a clinical study titled "Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)". The goal of this study is to evaluate the effects of varenicline versus nicotine replacement versus placebo on personal smoking environment cue (PSE) reactivity. The results of this study will inform whether first-line pharmacotherapies for nicotine dependence (e.g. nicotine patch, varenicline) alte...
What is the current status of trial NCT02551692?
This trial is currently completed. It is a NA study. The enrollment target is 125 participants. The study started on 2016-01. Estimated completion is 2019-01-07.
What interventions are being tested in trial NCT02551692?
The interventions under investigation include: Varenicline (DRUG), Placebo Nicotine Patch (DRUG), Nicotine Patch (DRUG), Placebo Capsule (DRUG).
Who is sponsoring clinical trial NCT02551692?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.